Page results
-
A new surgical technique could remove the risk of urinary incontinence after surgery to remove the prostate for men with prostate cancer.
-
This information is for UCLH patients with cancer or a blood condition who are being offered a PICC (peripherally inserted central catheter).
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
This page is for cancer patients receiving immunotherapy treatment.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
The Elizabeth Garrett Anderson maternity service at UCLH has been rated ‘Good’ following an inspection by the Care Quality Commission (CQC) in June 2023.
-
This page has been written for parents, carers and family members who are acting as carers and comforters for children and young people having radioactive mIBG treatment.
-
A new study at UCLH and UCL aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumour.
-
This information is for patients having gynaecology surgery who may also need bowel (colorectal) surgery as part of their cancer treatment.
File results
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0326 - Risk management system reporting rates for adverse events